Orthofix Medical Inc (OFIX)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $292.25M
Last updated: Nov 17, 2026 at 11:05 AM ET
Orthofix Medical Inc (OFIX) Earnings: Report Dates and Results
Orthofix Medical (OFIX) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Orthofix Medical reported EPS of -$0.15, above the -$0.31 estimate. It beat the EPS estimate in each of the last 17 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
OFIX has an expected report date of Feb 22, 2027.
OFIX Earnings Call
The latest OFIX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, OFIX beat 33 and missed 7. Revenue for the quarter ended Sep 30, 2026 was $207.86M, up 1.1% from $205.63M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.15 | -$0.31 | N/A | +51.61% | Beat | -175.0% | 1 | 1 up, 0 down | Nov 9, 2026 | $207.86M |
| Jun 30, 2026 | -$0.39 | -$0.46 | N/A | +15.22% | Beat | -400.0% | 1 | 1 up, 0 down | Aug 5, 2026 | $210.93M |
| Mar 31, 2026 | -$0.11 | -$0.29 | -$0.29 - -$0.29 | +62.07% | Beat | N/A | 1 | 0 up, 0 down | May 5, 2026 | $196.71M |
| Dec 31, 2025 | $0.24 | -$0.22 | N/A | +208.09% | Beat | +1444.2% | 2 | 1 up, 0 down | Feb 24, 2026 | $219.91M |
| Sep 30, 2025 | $0.20 | $0.12 | $0.12 - $0.12 | +66.67% | Beat | +185.7% | 1 | 0 up, 1 down | Nov 4, 2025 | $205.63M |
| Jun 30, 2025 | $0.13 | $0.04 | $0.04 - $0.04 | +225.00% | Beat | +160.0% | 1 | 0 up, 0 down | Aug 5, 2025 | $203.12M |
| Mar 31, 2025 | -$0.03 | -$0.27 | -$0.38 - -$0.17 | +88.89% | Beat | -127.3% | 3 | 0 up, 1 down | May 6, 2025 | $193.65M |
| Dec 31, 2024 | $0.02 | -$0.05 | -$0.12 - $0.08 | +130.80% | Beat | -48.7% | 3 | 0 up, 2 down | Feb 25, 2025 | $215.66M |
| Sep 30, 2024 | $0.07 | -$0.15 | -$0.20 - -$0.11 | +146.67% | Beat | 0.0% | 3 | 0 up, 0 down | Nov 7, 2024 | $196.61M |
| Jun 30, 2024 | $0.05 | -$0.19 | -$0.23 - -$0.13 | +126.32% | Beat | +150.0% | 3 | 0 up, 0 down | Aug 6, 2024 | $198.62M |
| Mar 31, 2024 | $0.11 | -$0.33 | -$0.35 - -$0.32 | +133.33% | Beat | N/A | 3 | 0 up, 0 down | May 7, 2024 | $188.61M |
| Dec 31, 2023 | $0.03 | -$0.08 | -$0.49 - $0.22 | +137.50% | Beat | -84.2% | 4 | 0 up, 0 down | Mar 5, 2024 | $200.41M |
| Sep 30, 2023 | $0.07 | -$0.21 | -$0.23 - -$0.18 | +133.33% | Beat | -46.2% | 4 | 0 up, 0 down | Nov 8, 2023 | $184.01M |
| Jun 30, 2023 | $0.02 | -$0.47 | -$0.67 - -$0.17 | +104.26% | Beat | -75.0% | 3 | 0 up, 0 down | Aug 8, 2023 | $187.02M |
| Mar 31, 2023 | -$0.10 | -$0.35 | -$0.83 - -$0.20 | +71.43% | Beat | N/A | 3 | 0 up, 1 down | May 9, 2023 | $175.20M |
| Dec 31, 2022 | $0.19 | $0.10 | N/A | +90.00% | Beat | -29.6% | 2 | 0 up, 0 down | Mar 6, 2023 | $122.23M |
| Sep 30, 2022 | $0.13 | $0.12 | $0.02 - $0.18 | +8.33% | Beat | +30.0% | 3 | 1 up, 0 down | Nov 3, 2022 | $114.00M |
| Jun 30, 2022 | $0.08 | $0.10 | N/A | -20.00% | Miss | -75.0% | N/A | 1 up, 1 down | Aug 5, 2022 | $118.07M |
| Mar 31, 2022 | -$0.10 | $0.09 | -$0.03 - $0.18 | -211.11% | Miss | -158.8% | 3 | 0 up, 0 down | May 6, 2022 | $106.42M |
| Dec 31, 2021 | $0.27 | $0.13 | $0.13 - $0.13 | +107.69% | Beat | -38.6% | 2 | N/A | Feb 25, 2022 | $125.06M |
| Sep 30, 2021 | $0.10 | $0.09 | $0.06 - $0.19 | +11.11% | Beat | -67.7% | 3 | N/A | Nov 5, 2021 | $112.43M |
| Jun 30, 2021 | $0.32 | $0.11 | $0.06 - $0.19 | +190.91% | Beat | N/A | 4 | N/A | Aug 6, 2021 | $121.39M |
| Mar 31, 2021 | $0.17 | $0.02 | -$0.05 - $0.18 | +750.00% | Beat | +88.9% | 4 | N/A | Apr 30, 2021 | $105.59M |
| Dec 31, 2020 | $0.44 | $0.19 | $0.14 - $0.27 | +131.58% | Beat | -13.7% | 4 | N/A | Feb 26, 2021 | $117.62M |
| Sep 30, 2020 | $0.31 | -$0.14 | -$1.27 - $0.07 | +321.43% | Beat | -24.4% | 5 | N/A | Nov 5, 2020 | $110.98M |
| Jun 30, 2020 | -$0.59 | -$0.75 | -$1.74 - -$0.70 | +21.33% | Beat | -310.7% | 3 | N/A | Aug 6, 2020 | $73.14M |
| Mar 31, 2020 | $0.09 | $0.06 | -$0.03 - $0.11 | +50.00% | Beat | -66.7% | 3 | N/A | May 8, 2020 | $104.82M |
| Dec 31, 2019 | $0.51 | $0.58 | $0.51 - $0.61 | -12.07% | Miss | -7.3% | 4 | N/A | Feb 24, 2020 | $121.49M |
| Sep 30, 2019 | $0.41 | $0.51 | $0.50 - $0.52 | -19.61% | Miss | -4.7% | 4 | N/A | Oct 28, 2019 | $113.50M |
| Jun 30, 2019 | $0.28 | $0.42 | $0.40 - $0.44 | -33.33% | Miss | -33.3% | 4 | N/A | Aug 5, 2019 | $115.85M |
| Mar 31, 2019 | $0.27 | $0.36 | $0.34 - $0.40 | -25.00% | Miss | -30.8% | 5 | N/A | May 6, 2019 | $109.11M |
| Dec 31, 2018 | $0.55 | $0.48 | $0.44 - $0.49 | +14.58% | Beat | +5.8% | 5 | N/A | Feb 25, 2019 | $121.08M |
| Sep 30, 2018 | $0.43 | $0.36 | $0.36 - $0.37 | +19.44% | Beat | +2.4% | 5 | N/A | Oct 29, 2018 | $111.71M |
| Jun 30, 2018 | $0.42 | $0.36 | $0.35 - $0.37 | +16.67% | Beat | 0.0% | 5 | N/A | Aug 6, 2018 | $111.55M |
| Mar 31, 2018 | $0.39 | $0.35 | $0.32 - $0.40 | +11.43% | Beat | +44.4% | 4 | N/A | Apr 30, 2018 | $108.71M |
| Dec 31, 2017 | $0.52 | $0.50 | $0.48 - $0.52 | +4.00% | Beat | +23.8% | 4 | N/A | Feb 26, 2018 | $116.90M |
| Sep 30, 2017 | $0.42 | $0.38 | $0.31 - $0.45 | +10.53% | Beat | +16.7% | 6 | N/A | Oct 30, 2017 | $105.25M |
| Jun 30, 2017 | $0.42 | $0.37 | $0.32 - $0.42 | +13.51% | Beat | +2.4% | 6 | N/A | Aug 7, 2017 | $108.94M |
| Mar 31, 2017 | $0.27 | $0.29 | N/A | -6.90% | Miss | -3.6% | N/A | N/A | May 4, 2017 | $102.74M |
| Dec 31, 2016 | $0.42 | $0.37 | N/A | +13.51% | Beat | +50.0% | N/A | N/A | Feb 27, 2017 | $108.54M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.54, up 119.2% from the year before. It was $1.47 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.54 | +119.2% |
| Dec 31, 2024 | $0.25 | +1127.0% |
| Dec 31, 2023 | $0.02 | -93.3% |
| Dec 31, 2022 | $0.30 | -65.1% |
| Dec 31, 2021 | $0.86 | +244.0% |
| Dec 31, 2020 | $0.25 | -83.0% |
| Dec 31, 2019 | $1.47 | -17.9% |
| Dec 31, 2018 | $1.79 | +9.8% |
| Dec 31, 2017 | $1.63 | +10.9% |
| Dec 31, 2016 | $1.47 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,700 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,728 | 8 | |
| 2026Q2 | Jun 30, 2026 | 4,028 | 6 | |
| 2026Q1 | Mar 31, 2026 | 3,720 | 8 | |
| 2025Q4 | Dec 31, 2025 | 4,841 | 8 | |
| 2025Q3 | Sep 30, 2025 | 3,357 | 7 | |
| 2025Q2 | Jun 30, 2025 | 4,602 | 8 | |
| 2025Q1 | Mar 31, 2025 | 5,403 | 8 | |
| 2024Q4 | Dec 31, 2024 | 5,422 | 8 |
2026Q3 Earnings Call
Opening remarks
Julie Dewey Chief IR and Communications Officer Thank you, and good morning, everyone. Welcome to Orthofix's third quarter 2026 earnings call. I'm Julie Dewey, Orthofix's Chief IR and Communications Officer. Joining me today are our President and Chief Executive Officer, Massimo Calafiore, and our Chief Financial Officer, Julie Andrews. Earlier today, Orthofix released financial results for the third quarter ended September 30, 2026. The press release and supplemental presentation are available on our Investor Relations website. A replay of this call will be posted shortly after we conclude. Before we begin, please note that our remarks include forward-looking statements. These statements involve risks and uncertainties, and actual results may differ materially. All statements other than those of historical fact are forward-looking statements. We do not undertake any obligation to revise or update such forward-looking statements, except as required by law. Factors that could cause actual results to differ materially are discussed in our most recent filings with the SEC and may be included in our future filings with the SEC. We will also reference certain non-GAAP financial measures during today's call, including certain growth rates presented on a pro forma constant currency basis and excluding discontinued M6 artificial disc product lines. Reconciliations to the most directly comparable U.S. GAAP measures and additional information are included in our press release and supplemental materials. Here's today's agenda. Massimo will begin with business performance and operational highlights. Julie Andrews will then review our financial results and guidance. After that, we'll open the call for questions. With that, I'll turn the call over to Massimo to discuss our third quarter performance. Massimo?
Massimo Calafiore President and Chief Executive Officer Thank you, Julie, and good morning, everyone. I appreciate you joining us today. While third quarter results were below our expectation, we saw continued strength in limb reconstruction and Therapeutic Solutions and further stabilization in U.S. Biologics. In U.S. Spine, market softness and unplanned supplier delays created inventory and instrument set constraints. We have a clear recovery plan and are accelerating actions to improve execution and position the business for stronger performance. We are concentrating resources behind our strongest partners and the highest-value technology, simplifying the portfolio and aligning costs with a more focused business. These actions are intended to establish a stronger foundation for growth, profitability, and cash generation over time. To recap these actions in more detail, first, we are concentrating resources behind our strongest commercial partners. We are accelerating exits from nonstrategic, lower-performing relationships and redeploying instrument sets to faster-growing core distributors. These distributors now generate around 80% of U.S. spinal implant revenue, with a similar concentration among core products. We have already seen these strategies work in markets where we consolidated distribution around stronger partners.
Frequently Asked Questions About OFIX
When is Orthofix Medical's next earnings date?
Orthofix Medical's next earnings report is expected for Feb 22, 2027.
Did OFIX beat earnings estimates last quarter?
Yes. Orthofix Medical reported EPS of -$0.15 for the quarter ended Sep 30, 2026, above the -$0.31 estimate, a 51.61% surprise.
What EPS do analysts expect from OFIX next quarter?
The consensus EPS estimate for Orthofix Medical for the quarter ending Dec 31, 2026 is -$0.07 from 4 analysts, with estimates from -$0.12 to -$0.02.
How often does OFIX beat earnings estimates?
Orthofix Medical beat the EPS estimate in each of the last 17 quarters, with an average surprise of +105.85%.
OFIX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors